OBJECTIVE: To evaluate three commercial typhoid rapid antibody tests for Salmonella Typhi antibodies in patients suspected of having typhoid fever in Mpumalanga, South Africa, and Moshi, United Republic of Tanzania. METHODS: The diagnostic accuracy of Cromotest(®) (semiquantitative slide agglutination and single tube Widal test), TUBEX(®) and Typhidot(®) was assessed against that of blood culture. Performance was modelled for scenarios with pretest probabilities of 5% and 50%. FINDINGS: In total 92 patients enrolled: 53 (57.6%) from South Africa and 39 (42.4%) from the United Republic of Tanzania. Salmonella Typhi was isolated from the blood of 28 (30.4%) patients. The semiquantitative slide agglutination and single-tube Widal tests had positive predictive values (PPVs) of 25.0% (95% confidence interval, CI: 0.6-80.6) and 20.0% (95% CI: 2.5-55.6), respectively. The newer typhoid rapid antibody tests had comparable PPVs: TUBEX(®), 54.1% (95% CI: 36.9-70.5); Typhidot(®) IgM, 56.7% (95% CI: 37.4-74.5); and Typhidot(®) IgG, 54.3% (95% CI: 36.6-71.2). For a pretest probability of 5%, PPVs were: TUBEX(®), 11.0% (95% CI: 6.6-17.9); Typhidot(®) IgM, 9.1% (95% CI: 5.8-14.0); and Typhidot(®) IgG, 11.0% (6.3-18.4). For a pretest probability of 50%, PPVs were: TUBEX(®), 70.2% (95% CI: 57.3-80.5); Typhidot(®) IgM, 65.6% (95% CI: 54.0-75.6); and Typhidot(®) IgG, 70.0% (95% CI: 56.0-81.1). CONCLUSION: Semiquantitative slide agglutination and single-tube Widal tests performed poorly. TUBEX(®) and Typhidot(®) may be suitable when pretest probability is high and blood cultures are unavailable, but their performance does not justify deployment in routine care settings in sub-Saharan Africa.
OBJECTIVE: To evaluate three commercial typhoid rapid antibody tests for Salmonella Typhi antibodies in patients suspected of having typhoid fever in Mpumalanga, South Africa, and Moshi, United Republic of Tanzania. METHODS: The diagnostic accuracy of Cromotest(®) (semiquantitative slide agglutination and single tube Widal test), TUBEX(®) and Typhidot(®) was assessed against that of blood culture. Performance was modelled for scenarios with pretest probabilities of 5% and 50%. FINDINGS: In total 92 patients enrolled: 53 (57.6%) from South Africa and 39 (42.4%) from the United Republic of Tanzania. Salmonella Typhi was isolated from the blood of 28 (30.4%) patients. The semiquantitative slide agglutination and single-tube Widal tests had positive predictive values (PPVs) of 25.0% (95% confidence interval, CI: 0.6-80.6) and 20.0% (95% CI: 2.5-55.6), respectively. The newer typhoid rapid antibody tests had comparable PPVs: TUBEX(®), 54.1% (95% CI: 36.9-70.5); Typhidot(®) IgM, 56.7% (95% CI: 37.4-74.5); and Typhidot(®) IgG, 54.3% (95% CI: 36.6-71.2). For a pretest probability of 5%, PPVs were: TUBEX(®), 11.0% (95% CI: 6.6-17.9); Typhidot(®) IgM, 9.1% (95% CI: 5.8-14.0); and Typhidot(®) IgG, 11.0% (6.3-18.4). For a pretest probability of 50%, PPVs were: TUBEX(®), 70.2% (95% CI: 57.3-80.5); Typhidot(®) IgM, 65.6% (95% CI: 54.0-75.6); and Typhidot(®) IgG, 70.0% (95% CI: 56.0-81.1). CONCLUSION: Semiquantitative slide agglutination and single-tube Widal tests performed poorly. TUBEX(®) and Typhidot(®) may be suitable when pretest probability is high and blood cultures are unavailable, but their performance does not justify deployment in routine care settings in sub-Saharan Africa.
Authors: John A Crump; Habib O Ramadhani; Anne B Morrissey; Levina J Msuya; Lan-Yan Yang; Shein-Chung Chow; Susan C Morpeth; Hugh Reyburn; Boniface N Njau; Andrea V Shaw; Helmut C Diefenthal; John A Bartlett; John F Shao; Werner Schimana; Coleen K Cunningham; Grace D Kinabo Journal: Trop Med Int Health Date: 2011-04-07 Impact factor: 2.622
Authors: Stanley Mirrett; L Barth Reller; Cathy A Petti; Christopher W Woods; Bindu Vazirani; Rekha Sivadas; Melvin P Weinstein Journal: J Clin Microbiol Date: 2003-06 Impact factor: 5.948
Authors: C M Parry; N T Hoa; T S Diep; J Wain; N T Chinh; H Vinh; T T Hien; N J White; J J Farrar Journal: J Clin Microbiol Date: 1999-09 Impact factor: 5.948
Authors: Valentine Siba; Paul F Horwood; Kilagi Vanuga; Johanna Wapling; Rebecca Sehuko; Peter M Siba; Andrew R Greenhill Journal: Clin Vaccine Immunol Date: 2012-09-19
Authors: José Luis Villarreal Camacho; Evelyn Mendoza Torres; Christian Cadena; Julieth Prieto; Lourdes Luz Varela Prieto; Daniel Antonio Villanueva Torregroza Journal: J Clin Lab Anal Date: 2013-05 Impact factor: 2.352
Authors: Vera von Kalckreuth; Frank Konings; Peter Aaby; Yaw Adu-Sarkodie; Mohammad Ali; Abraham Aseffa; Stephen Baker; Robert F Breiman; Morten Bjerregaard-Andersen; John D Clemens; John A Crump; Ligia Maria Cruz Espinoza; Jessica Fung Deerin; Nagla Gasmelseed; Amy Gassama Sow; Justin Im; Karen H Keddy; Leonard Cosmas; Jürgen May; Christian G Meyer; Eric D Mintz; Joel M Montgomery; Beatrice Olack; Gi Deok Pak; Ursula Panzner; Se Eun Park; Raphaël Rakotozandrindrainy; Heidi Schütt-Gerowitt; Abdramane Bassiahi Soura; Michelle R Warren; Thomas F Wierzba; Florian Marks Journal: Clin Infect Dis Date: 2016-03-15 Impact factor: 9.079
Authors: Josée Castonguay-Vanier; Viengmon Davong; Latsanyphone Bouthasavong; Davanh Sengdetka; Manivone Simmalavong; Amphayvanh Seupsavith; David A B Dance; Stephen Baker; Tu Le Thi Phuong; Manivanh Vongsouvath; Paul N Newton Journal: J Clin Microbiol Date: 2012-10-24 Impact factor: 5.948